Lilly and Merck pair 'breakthrough' therapies in latest cancer collaboration

Eli Lilly ($LLY) and Merck ($MRK) are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. Lilly is planning to sponsor a Phase I study combining its abemaciclib, a late-stage CDK 4/6 inhibitor, with Merck's Keytruda, which blocks the protein PD-1 to marshal an immune attack on tumor cells. The idea is to see whether the two drugs in tandem can make a difference in a variety of cancer types, and Lilly plans to embark on a Phase II effort if early signs are positive. Abemaciclib, which received the FDA's breakthrough therapy designation in October, is in late-stage development as a treatment for breast and lung cancers. Merck's therapy, another breakthrough designee, is approved in melanoma and lung cancer. Release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.